泰格醫藥(03347.HK)參與投資博遠二期人民幣基金 認繳出資5,000萬人幣
泰格醫藥(03347.HK)公布,投資平台杭州泰格股權投資合伙企業擬以自有資金投資博遠二期人民幣基金(下稱合伙企業)。合伙企業的目標認繳出資總額為15億元至20億元人民幣(下同),公司將作為該合伙企業的有限合伙人認繳出資5,000萬元。
合夥企業主要投資有增長潛力、優質的醫療健康產業相關企業或其他經濟實體,包括但不限於運營醫藥、生物科技、醫療服務、醫療器械、設備、診斷,動物保健,及其他醫療健康相關領域的企業。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.